Navigation Links
Initiation of Lantus® Leads to Better Glycemic Control at Similar Weight Gain Versus Other Comparators in Patients With Type 2 Diabetes
Date:9/12/2011

the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Reference: (1) Lower weight gain and better outcomes in patients with type 2 diabetes starting insulin treatment when baseline A1C <8 percent: Abstract No: 670

3/3

Contacts:     US CommunicationsGlobal Communications

 

Susan Brooks

Yanyan Chang

 

T. 908-981-6566

T. +49 69 305 22283

 

Susan.Brooks@sanofi.com

Yanyan.chang@sanofi.com  

 

 
    Corporate Media Relations    

Marisol Peron    
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
2. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
3. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
4. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
5. Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052)
6. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
7. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
8. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
9. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
10. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
11. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- According to the American Optometric Association (AOA), parents severely ... An AOA survey reports that 83 percent of children ... use an electronic device for three or more hours ... revealed that only 40 percent of parents believe their ... of time. Eye doctors are concerned that this significant ...
(Date:7/22/2014)... 2014  NeuroSigma, Inc. (NeuroSigma), a California ... its non-invasive Monarch ™ eTNS™ Therapy ... announced that enrollment has begun in a pediatric open ... adjunctive therapy for the treatment of Lennox-Gastaut Syndrome (LGS). ... Olive View-UCLA Medical Center in Sylmar, California ...
(Date:7/21/2014)... , July 21, 2014 McCord Research, ... (U.S. Patent No. 8,796,315). This patent describes a ... healing.  According to the inventor, Dr. McCord, this ... require wound healing, a composition of an effective ... from umbilical cord blood, such that the administration ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2
... Calif., Feb. 7, 2012  Cardica, Inc. (Nasdaq: CRDC ) ... market and other conditions, shares of its common stock in an ... or when the offering may be completed, or as to the ... Sciences is acting as sole book-running manager for the offering. ...
... 2012  Prometheus Laboratories Inc., a specialty pharmaceutical and ... research and collaboration agreement with an unnamed leading ... proprietary oncology diagnostic platform (CEER) to develop diagnostic ... CEER arrays may ultimately be used in clinical ...
Cached Medicine Technology:Cardica Announces Proposed Public Offering of Common Stock 2Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company 2
(Date:7/22/2014)... 2014 Bramal LED announced that they will ... Begley Jr, airing later this year via Discovery Channel. Dates ... learn about Bramal LED’s T-10 lamps, which provide over 80,000 ... up to 70 percent. Bramal LED’s T-10 lamps can be ... seconds or on direct AC voltage, with no need for ...
(Date:7/22/2014)... 2014 Chris Carpenter’s Info Cash ... takes a comprehensive, step-by-step approach to teaching the techniques ... has just been released to the public, prompting a ... marketing world if you’re unable to generate traffic you’re ... people simply give up when they find traffic generation ...
(Date:7/22/2014)... NY (PRWEB) July 22, 2014 BlackBox ... Blast Gauge™ System with advancements including a ... The new gauges represent a functional revision of the ... capability to capture complex data on blast events by ... resulting accelerations. The extreme changes in overpressure that accompany ...
(Date:7/22/2014)... BESLER Consulting, a leading provider of ... is pleased to offer a complimentary version of ... hospitals with analyzing their 2015 QualityNet Hospital-Specific Reports ... 21 allow hospitals to validate their Medicare readmissions ... data contained in these reports can be cumbersome ...
(Date:7/22/2014)... One woman who looked at diet pills ... pounds. Unfortunately, the weight loss came at a price – ... her time using the pill, and says her personality changed ... insomnia as a result of the caffeine content of one ... age of 37 because of a diet pill she was ...
Breaking Medicine News(10 mins):Health News:Bramal LED to be featured in Upcoming Episode of Innovations with Ed Begley, Jr. 2Health News:Info Cash 2.0: Review Of Chris Carpenter’s Online Marketing Training Released 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 3Health News:Complimentary Re-admissions Analytics Tool Available From BESLER Consulting 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2
... Mercedes Walton, CEO of Cryo-Cell International, one of the ... progress to date and encouraging continued momentum for existing bills through ... Cord Blood Banking Act," and H.R. 2107, the "Cord Blood Education ... progress from the first half of the year to enable and ...
... Sociological Association,s 104th annual meeting, will be the subject ... present research and explore the politics, history, health and ... More than 5,000 sociologists will convene in the ... New Politics of Community," the meeting,s theme. In addition ...
... , SAN DIEGO, July 6 ADVENTRX Pharmaceuticals, Inc. ... it has completed the previously announced sale of shares ... to a registered direct offering to a single institutional ... percent, or approximately $340,250, of the gross proceeds will ...
... showed muscle fiber damage even after halting drugs, researchers say ... used to lower cholesterol, may cause structural damage to the ... study has found. , The damage may occur even when ... and may persist even after statin use is halted, according ...
... Eli Lilly and Company (NYSE: LLY ) will ... Wednesday, July 22, 2009. Lilly will also conduct a conference ... further detail the company,s financial performance. , , The ... EDT. Investors, media and the general public can access a ...
... Inc. (Nasdaq: SLTM ), a global leader in ... an amendment with Silicon Valley Bank, a member company of ... the company,s credit facility has been expanded from $9 million ... the secured revolving loan facility to $8.0 million, an amendment ...
Cached Medicine News:Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 2Health News:Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood 3Health News:Sociologists to turn the sociological eye on San Francisco 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 2Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 3Health News:ADVENTRX Pharmaceuticals Announces Closing of Financing 4Health News:Statins May Cause Muscle Damage in Some Patients 2Health News:Statins May Cause Muscle Damage in Some Patients 3Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 2Health News:Solta Medical, Inc. Signs Amendment to Expand Its Credit Facility With Silicon Valley Bank 3
... Shepard Clear Corneal Diamond Knife is a ... Dennis Shepard of Santa Maria, California. This ... Shepard's need for a quality instrument that ... Corneal Surgical technique. Through professional collaboration between ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
... Software is a new approach to practice management, ... face in todays healthcare market. OPIE was created ... who work exclusively in this field, so it ... functional and easy-to-use than anything else available. If ...
... The DioLite 532 laser is ... and pigmented skin lesions such as ... port wine stains, lentigines, dermatosis papulosis ... technology offers unsurpassed reliability, a selection ...
Medicine Products: